The 14 linked references in paper Aleksandr Markovsky V., А. Марковский В. (2018) “АДДИТИВНЫЙ ЭФФЕКТ ПОЛИМОРФИЗМА ГЕНОВ БЕЛКОВ ФОЛАТНОГО ОБМЕНА И УРОВЕНЬ ГОМОЦИСТЕИНА У БОЛЬНЫХ ПРОЛИФЕРАТИВНЫМИ ЗАБОЛЕВАНИЯМИ МОЛОЧНОЙ ЖЕЛЕЗЫ КАК ПОТЕНЦИАЛЬНЫЙ ФАКТОР РИСКА ТРОМБОЗОВ // ADDITIVE EFFECT OF GENES POLYMORPHISM OF FOLATE CYCLE PROTEINS AND HOMOCYSTEIN LEVEL IN PATIENTS WITH PROLIFERATIVE DISEASES OF THE BREAST AS A POTENTIAL FACTOR OF THE RISK OF THROMBOSSES” / spz:neicon:aterotromboz:y:2018:i:2:p:46-53

  1. Horsted F., West J., Grainge M.J. Risk of Venous thromboembolism in Patients with Cancer: A systematic Review and Meta-Analysis. PLoS med. 2012; 9(7): e1001275. doi: 10.1371/journal. p m e d.10 01275.
  2. ouyang s., Li Y., Liu Z. et al. Association between MtR A2756G and MtRR A66G polymorphisms and maternal risk for neural tube defects: a meta-analysis. Gene. 2013; 515(2): 308-12. doi: 10.1016/j.gene.2012.11.070.
  3. Марковский А.В., Страмбовская Н.Н., Терешков П.П. Молекулярно-генетические и сывороточные маркеры нарушений фолатного обмена у больных пролиферативными заболеваниями и раком молочной железы. Сибирский онкологический журнал. 2017; 16(2): 50–55. doi: 10.21294/181448612017-16-2-50-55. / Markovsky A.V., strambovskaya n.n ., tereshkov P.P. Molecular-genetic and serum markers of folate metabolism deficiency in patients with proliferative breast disease and breast cancer. Siberian Journal of Oncology. 2017; 16(2): 50–55. doi: 10.21294/18144861-2017-16-2-50-55. (the paper at Socionet)
  4. Khan U.t., Walker A.J., Baig s. et al. Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BmC Cancer. 2017; 17(1): 747. doi: 10.1186/s12885-0173719 -1 .
  5. 18821/1028-9984-2017-22-4-203-208. / shilova A.n., shkoda o.s., Lomivorotov V.V. et al. Association of the folate metabolism genes with the risk for lung, prostate, breast and uterine cancer. russian Cancer Journal. 2017; 22(4): 203-208. doi: 10.18821/10289984-2017-22-4-203-208. 10. Баркаган З.С., Костюченко Г.И., Котовщикова Е.Ф. Гипергомоцистеинемия как самостоятельный фактор риска поражения и тромбирования кровеносных сосудов. Патология кровообращения и кардиохирургия. 2002; 1: 65–71. / Barkagan Z.s., Kostyuchenko G.I., Kotovshchikova e.F. Hyperhomocysteinemia as independent risk factor of blood vessels lesion and thrombosing. Pathology of circulation and heart surgery. 2002; 1: 65–71.
  6. Foy P., Moll s. thrombophilia: 2009 Update. Curr Treat Options Cardio med. 2009; 11(2): 114-128. https: //doi. org/10.1007/s11936-009-0012-x.
  7. Pasta L., Pasta F., D’Amico M. PAI-1 4G-4G, MtHFR 677tt, V Leiden 506Q, and Prothrombin 20210A in splanchnic Vein thrombosis: Analysis of Individual Patient Data From three Prospective studies. J Clin Exp Hepatol. 2016 Mar; 6(1): 10-4. doi: 10.1016/j. jceh.2015.11.002.
  8. Falvella F.s., Cremolini C., Miceli R. et al. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics J. 2017; 17(4): 331-336. doi: 10.1038/tpj.2016.22.
  9. Zhao M., Wang X. et al. Homocysteine and stroke Risk: Modifying effect of Methylenetetrahydrofolate Reductase C677t Polymorphism and Folic Acid Intervention. Stroke. 2017; 48(5): 1183–1190. doi: 10.1161/stRoKeAHA.116.015324.
  10. Yates Z., Lucock M. Interaction between common folate polymorphisms and B-vitamin nutritional status modulates homocysteine and risk for a thrombotic event. mol Genet metab. 2003; 79(3): 201-213. doi: https: //doi.org/10.1016/s1096-7192(03)00093-3.
  11. naushad s.M., Jain Jamal M.n., Prasad C.K. Relationship between methionine synthase, methionine synthase reductase genetic polymorphisms and deep vein thrombosis among south Indians. Clin Chem Lab med. 2008; 46(1): 73-79. doi: 10.1515/ CCLM.2008.021.
  12. Harmon D.L., shields D.C., Woodside J.V. et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol. 1999; 17(4): 298-309. doi: 10.1002/(sICI)1098-2272(199911)17: 4<298: : AID-GePI5>3.0.Co, 2-V.
  13. Ray J.G. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm med. 2008; 14(5): 369-373. doi: 10.1097/MCP.0b013e328307ee38.
  14. Heijer M., Lewington s., Clarke R. Homocysteine, MtHFR and risk of venous thrombosis a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3: 292-299. doi: 10.1111/j.15387836.2005.01141.x.